Suppr超能文献

基于指南的心衰住院后治疗的真实世界分析。

Real-World Analysis of Guideline-Based Therapy After Hospitalization for Heart Failure.

机构信息

Amgen Inc. Thousand Oaks CA.

Humana Healthcare Research Inc. Louisville KY.

出版信息

J Am Heart Assoc. 2020 Aug 18;9(16):e015042. doi: 10.1161/JAHA.119.015042. Epub 2020 Aug 4.

Abstract

Background Patients hospitalized with heart failure (HF) with reduced ejection fraction have high risk of rehospitalization or death. Despite guideline recommendations based on high-quality evidence, a substantial proportion of patients with HF with reduced ejection fraction receive suboptimal care and/or do not comply with optimal care following hospitalization. Methods and Results This retrospective observational study identified 17 106 patients with HF with reduced ejection fraction with an incident HF-related hospitalization using the Humana Medicare Advantage database (2008-2016). HF medication classes (beta-blockers, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, angiotensin receptor neprilysin inhibitors, or mineralocorticoid receptor antagonists) received in the year after hospitalization were recorded, and categorized by treatment intensity (ie, number of concomitant medication classes received: none [23% of patients; n=3987], monotherapy [22%; n=3777], dual therapy [41%; n=7056], or triple therapy [13%; n=2286]). Compared with no medication, risk of primary outcome (composite of death or rehospitalization) was significantly reduced (hazard ratio [95% CI]) with monotherapy (0.68 [0.64-0.71]), dual therapy (0.56 [0.53-0.59]), and triple therapy (0.45 [0.41-0.50]). Nearly half (46%) of patients who received post-discharge medication had no dose escalation. Overall, 59% of patients had follow-up with a primary care physician within 14 days of discharge, and 23% had follow-up with a cardiologist. Conclusions In real-world clinical practice, increasing treatment intensity reduced risk of death and rehospitalization among patients hospitalized for HF, though the use of guideline-recommended dual and triple HF therapy remained low. There are opportunities to improve post-discharge medical management for patients with HF with reduced ejection fraction such as optimizing dose titration and improving post-discharge follow-up with providers.

摘要

背景

射血分数降低的心力衰竭(HF)住院患者再住院或死亡风险较高。尽管基于高质量证据的指南建议,但射血分数降低的心力衰竭患者中有相当一部分接受的治疗不理想,或者在住院后不遵守最佳治疗方案。

方法和结果

本回顾性观察性研究使用 Humana Medicare Advantage 数据库(2008-2016 年),确定了 17106 例射血分数降低的心力衰竭患者的心力衰竭相关住院事件。记录了住院后一年内接受的心力衰竭药物类别(β受体阻滞剂、血管紧张素转换酶抑制剂、血管紧张素受体阻滞剂、血管紧张素受体脑啡肽酶抑制剂或盐皮质激素受体拮抗剂),并按治疗强度进行分类(即,同时接受的药物类别数量:无[23%的患者;n=3987]、单药治疗[22%;n=3777]、双药治疗[41%;n=7056]或三药治疗[13%;n=2286])。与未用药物治疗相比,主要结局(死亡或再住院的复合终点)的风险显著降低(风险比[95%CI]):单药治疗为 0.68[0.64-0.71],双药治疗为 0.56[0.53-0.59],三药治疗为 0.45[0.41-0.50]。接受出院后药物治疗的患者中,近一半(46%)未进行剂量升级。总体而言,59%的患者在出院后 14 天内接受了初级保健医生的随访,23%的患者接受了心脏病专家的随访。

结论

在真实世界的临床实践中,增加治疗强度降低了因心力衰竭住院患者的死亡和再住院风险,但指南推荐的双药和三药心力衰竭治疗的使用率仍然较低。有机会改善射血分数降低的心力衰竭患者出院后的医疗管理,例如优化剂量滴定和改善出院后与提供者的随访。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0120/7660806/e809513d3b4a/JAH3-9-e015042-g001.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验